XML 30 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Non- controlling Interest
Beginning balance at Sep. 30, 2022 $ 418,339 $ 198 $ 1,219,213 $ (136) $ (820,755) $ 19,819
Beginning balance (in shares) at Sep. 30, 2022   105,960,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 19,390   19,390      
Exercise of stock options 576   576      
Exercise of stock options (in shares)   82,000        
Common stock - restricted stock units vesting 0 $ 1 (1)      
Common stock - restricted stock units vesting (in shares)   98,000        
Foreign currency translation adjustments (122)     (122)    
Net income (loss) (41,811)       (41,325) (486)
Ending balance at Dec. 31, 2022 396,372 $ 199 1,239,178 (258) (862,080) 19,333
Ending balance (in shares) at Dec. 31, 2022   106,140,000        
Beginning balance at Sep. 30, 2022 418,339 $ 198 1,219,213 (136) (820,755) 19,819
Beginning balance (in shares) at Sep. 30, 2022   105,960,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Foreign currency translation adjustments (196)          
Change in unrealized losses on available-for-sale securities 0          
Net income (loss) 5,865          
Ending balance at Mar. 31, 2023 465,106 $ 199 1,260,310 (332) (813,405) 18,334
Ending balance (in shares) at Mar. 31, 2023   106,869,000        
Beginning balance at Dec. 31, 2022 396,372 $ 199 1,239,178 (258) (862,080) 19,333
Beginning balance (in shares) at Dec. 31, 2022   106,140,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 20,612   20,612      
Exercise of stock options 520   520      
Exercise of stock options (in shares)   64,000        
Common stock - restricted stock units vesting (in shares)   665,000        
Foreign currency translation adjustments (74)     (74)    
Change in unrealized losses on available-for-sale securities 0          
Net income (loss) 47,676       48,675 (999)
Ending balance at Mar. 31, 2023 465,106 $ 199 1,260,310 (332) (813,405) 18,334
Ending balance (in shares) at Mar. 31, 2023   106,869,000        
Beginning balance at Sep. 30, 2023 287,162 $ 200 1,300,395 (3,222) (1,026,030) 15,819
Beginning balance (in shares) at Sep. 30, 2023   107,312,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 19,694   19,694      
Exercise of stock options 267   267      
Exercise of stock options (in shares)   34,000        
Common stock - restricted stock units vesting (in shares)   154,000        
Foreign currency translation adjustments 58     58    
Change in unrealized losses on available-for-sale securities 1,909     1,909    
Net income (loss) (135,376)       (132,864) (2,512)
Ending balance at Dec. 31, 2023 173,714 $ 200 1,320,356 (1,255) (1,158,894) 13,307
Ending balance (in shares) at Dec. 31, 2023   107,500,000        
Beginning balance at Sep. 30, 2023 $ 287,162 $ 200 1,300,395 (3,222) (1,026,030) 15,819
Beginning balance (in shares) at Sep. 30, 2023   107,312,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares) 154,347          
Foreign currency translation adjustments $ 2          
Change in unrealized losses on available-for-sale securities 2,125          
Net income (loss) (262,372)          
Ending balance at Mar. 31, 2024 495,405 $ 217 1,768,866 (1,095) (1,284,194) 11,611
Ending balance (in shares) at Mar. 31, 2024   124,133,000        
Beginning balance at Dec. 31, 2023 173,714 $ 200 1,320,356 (1,255) (1,158,894) 13,307
Beginning balance (in shares) at Dec. 31, 2023   107,500,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 17,750   17,750      
Exercise of stock options 1,512   1,512      
Exercise of stock options (in shares)   120,000        
Common stock - restricted stock units vesting 0 $ 1 (1)      
Common stock - restricted stock units vesting (in shares)   723,000        
Common stock issued, net of offering costs 429,265 $ 16 429,249      
Common stock issued, net of offering costs (in shares)   15,790,000        
Foreign currency translation adjustments (56)     (56)    
Change in unrealized losses on available-for-sale securities 216     216    
Net income (loss) (126,996)       (125,300) (1,696)
Ending balance at Mar. 31, 2024 $ 495,405 $ 217 $ 1,768,866 $ (1,095) $ (1,284,194) $ 11,611
Ending balance (in shares) at Mar. 31, 2024   124,133,000